The BCRF Collection

The BCRF Collection

The BCRF Collection

Power of Pink

Power of Pink

Power of Pink

One hundred percent of net profits from the sale of pink rubber bracelets, and 20% of sales from select other designs, will be donated to the Breast Cancer Research Foundation to help advance their research and find a cure for breast cancer.*

One hundred percent of net profits from the sale of pink rubber bracelets, and 20% of sales from select other designs, will be donated to the Breast Cancer Research Foundation to help advance their research and find a cure for breast cancer.*

One hundred percent of net profits from the sale of pink rubber bracelets, and 20% of sales from select other designs, will be donated to the Breast Cancer Research Foundation to help advance their research and find a cure for breast cancer.*

An image of three ribbon necklaces.
Shop the look
Cable Collectibles Ribbon Chain Bracelet in 18K Rose Gold with Pavé, 15mmCable Collectibles Ribbon Chain Bracelet in 18K Rose Gold with Pavé, 15mm

Charitable

Cable Collectibles® Ribbon Chain Bracelet 15mm

$1,450

18K Rose Gold with Pavé

null
Cable Collectibles® Ribbon Chain Bracelet in Sterling Silver with Pavé Pink Sapphires, 1.5mmCable Collectibles® Ribbon Chain Bracelet in Sterling Silver with Pavé Pink Sapphires, 1.5mm

Charitable

Cable Collectibles® Ribbon Chain Bracelet in Sterling Silver with Pavé Pink Sapphires, 1.5mm
Cable Collectibles® Ribbon Chain Bracelet in Sterling Silver with Pink Enamel, 1.5mm

Cable Collectibles® Ribbon Chain Bracelet 1.5mm

$450 - $550

Sterling Silver

Cable Collectibles® Ribbon Chain Bracelet in Sterling Silver with Pavé Pink Sapphires, 1.5mm
Cable Collectibles® Ribbon Chain Bracelet in Sterling Silver with Pink Enamel, 1.5mm
null
Cable Collectibles® Ribbon Necklace in 18K Rose Gold with Pavé Pink Sapphires, 15.7mmCable Collectibles® Ribbon Necklace in 18K Rose Gold with Pavé Pink Sapphires, 15.7mm

Charitable

Cable Collectibles® Ribbon Necklace 15.7mm

$975

18K Rose Gold with Pavé

null
Cable Collectibles® Ribbon Necklace in Sterling Silver with Pink Sapphires, 24.4mmCable Collectibles® Ribbon Necklace in Sterling Silver with Pink Sapphires, 24.4mm

Charitable

Cable Collectibles® Ribbon Necklace in Sterling Silver with Pink Sapphires, 24.4mm
Cable Collectibles® Ribbon Necklace in Sterling Silver with Pink Enamel, 24.4mm

Cable Collectibles® Ribbon Necklace 24.4mm

$495 - $595

Sterling Silver

Cable Collectibles® Ribbon Necklace in Sterling Silver with Pink Sapphires, 24.4mm
Cable Collectibles® Ribbon Necklace in Sterling Silver with Pink Enamel, 24.4mm
null
Cable Collectibles® Ribbon Pin in Sterling Silver with Pink Enamel, 18mmCable Collectibles® Ribbon Pin in Sterling Silver with Pink Enamel, 18mm

Charitable

Cable Collectibles® Ribbon Pin 18mm

$200

Sterling Silver

null
Cable Bracelet in Pink Rubber, 6mmCable Bracelet in Pink Rubber, 6mm

Charitable

Cable Bracelet 6mm

$20

Pink Rubber

null
Cable Bracelet in Pink Rubber, 10mmCable Bracelet in Pink Rubber, 10mm

Charitable

Cable Bracelet 10mm

$20

Pink Rubber

null

The Promise of Research

The Promise of Research

The Promise of Research

For 16 years, David Yurman has helped support the Breast Cancer Research Foundation’s global research cohort, which has been behind major breakthroughs in breast cancer prevention, diagnosis, treatment, survivorship, and metastasis.

For 16 years, David Yurman has helped support the Breast Cancer Research Foundation’s global research cohort, which has been behind major breakthroughs in breast cancer prevention, diagnosis, treatment, survivorship, and metastasis.

For 16 years, David Yurman has helped support the Breast Cancer Research Foundation’s global research cohort, which has been behind major breakthroughs in breast cancer prevention, diagnosis, treatment, survivorship, and metastasis.

To date, David Yurman has donated over $3 million to BCRF.

To date, David Yurman has donated over $3 million to BCRF.

To date, David Yurman has donated over $3 million to BCRF.

Meet Dr. Hayley McDaid, a New York-based scientist whose current research focuses on identifying new therapeutic options for triple-negative and BRCA-driven breast cancers, and Dr. Sarat Chandarlapaty, a New York-based medical oncologist studying how and why breast cancers become resistant to treatment. These incredible doctors were kind enough to sit with us and share their specific areas of research.

Meet Dr. Hayley McDaid, a New York-based scientist whose current research focuses on identifying new therapeutic options for triple-negative and BRCA-driven breast cancers, and Dr. Sarat Chandarlapaty, a New York-based medical oncologist studying how and why breast cancers become resistant to treatment. These incredible doctors were kind enough to sit with us and share their specific areas of research.

Meet Dr. Hayley McDaid, a New York-based scientist whose current research focuses on identifying new therapeutic options for triple-negative and BRCA-driven breast cancers, and Dr. Sarat Chandarlapaty, a New York-based medical oncologist studying how and why breast cancers become resistant to treatment. These incredible doctors were kind enough to sit with us and share their specific areas of research.

Why did you decide to focus on breast cancer research?

Why did you decide to focus on breast
cancer research?

DR. McDAID: My laboratory studies cancer drugs known as tubulin inhibitors, of which paclitaxel and docetaxel are best known. They are primarily used in the treatment of HER2+ and triple negative breast cancers. Women with metastatic breast cancer respond well to paclitaxel, but some develop resistance over time—I hope to help develop more efficacious, safe tubulin inhibitors for those patients.

DR. CHANDARLAPATY: I was working in the laboratory on a protein called HER2 that supports the growth of many different types of cancer and is especially common in breast cancer. Then I saw patients with breast cancer receiving anti-HER2 therapies that worked initially, but stopped working after a few years. This became a major focus of our research: how and why do breast cancers develop resistance to therapies that are designed to target their unique features?

DR. McDAID: My laboratory studies cancer drugs known as tubulin inhibitors, of which paclitaxel and docetaxel are best known. They are primarily used in the treatment of HER2+ and triple negative breast cancers. Women with metastatic breast cancer respond well to paclitaxel, but some develop resistance over time—I hope to help develop more efficacious, safe tubulin inhibitors for those patients.

DR. CHANDARLAPATY: I was working in the laboratory on a protein called HER2 that supports the growth of many different types of cancer and is especially common in breast cancer. Then I saw patients with breast cancer receiving anti-HER2 therapies that worked initially, but stopped working after a few years. This became a major focus of our research: how and why do breast cancers develop resistance to therapies that are designed to target their unique features?

What area of breast cancer research do you focus on specifically?

Dr. McDAID: Triple negative breast cancer (TNBC) remains one of the most recalcitrant forms of breast cancer, particularly for patients who have inherited mutations in the BRCA1/2 genes. While tubulin inhibitors are still effective for these patients, response rates are lower, and patients can relapse and develop metastatic disease that is resistant to drugs. Even after therapy, some breast cancer cells aren’t killed, but become dormant, and resume growth at a later stage. My lab is developing novel tubulin inhibitors that induce cancer cell death even in TNBCs that no longer respond to drugs like paclitaxel. Another new benefit of these drugs is inducing a very stable form of dormancy that limits the ability of surviving tumor cells to grow back, or to metastasize. We are hopeful that this approach can help women with recalcitrant disease who need additional treatment choices.

DR. CHANDARLAPATY: We focus on two major types of breast cancer: those that have the receptor for the estrogen hormone, and those that have the HER2 receptor. Our lab is interested in understanding how these cancers evolve and develop resistance to anti-estrogens and anti-HER2 therapies, and then devising ways to combat these patterns of resistance. For instance, we found that breast cancers that are exposed to antiestrogen therapy develop mutations that cause the estrogen receptor to remain active, even without any estrogen. So we developed and studied drugs that can target those mutant estrogen receptors. At the same time, we’re studying the evolutionary process that allowed the breast tumors to develop those mutations, so that we can develop treatments that will prevent the mutations from occurring in the first place.

DR. CHANDARLAPATY: We focus on two major types of breast cancer: those that have the receptor for the estrogen hormone, and those that have the HER2 receptor. Our lab is interested in understanding how these cancers evolve and develop resistance to anti-estrogens and anti-HER2 therapies, and then devising ways to combat these patterns of resistance. For instance, we found that breast cancers that are exposed to antiestrogen therapy develop mutations that cause the estrogen receptor to remain active, even without any estrogen. So we developed and studied drugs that can target those mutant estrogen receptors. At the same time, we’re studying the evolutionary process that allowed the breast tumors to develop those mutations, so that we can develop treatments that will prevent the mutations from occurring in the first place.

DR. CHANDARLAPATY: We focus on two major types of breast cancer: those that have the receptor for the estrogen hormone, and those that have the HER2 receptor. Our lab is interested in understanding how these cancers evolve and develop resistance to anti-estrogens and anti-HER2 therapies, and then devising ways to combat these patterns of resistance. For instance, we found that breast cancers that are exposed to antiestrogen therapy develop mutations that cause the estrogen receptor to remain active, even without any estrogen. So we developed and studied drugs that can target those mutant estrogen receptors. At the same time, we’re studying the evolutionary process that allowed the breast tumors to develop those mutations, so that we can develop treatments that will prevent the mutations from occurring in the first place.

inducing a very stable form of dormancy that limits the ability of surviving tumor cells to grow back, or
to metastasize. We are hopeful that this approach can help women with recalcitrant disease who need
additional treatment choices.

DR. CHANDARLAPATY: We focus on two major types of breast cancer: those that have the receptor
for the estrogen hormone, and those that have the HER2 receptor. Our lab is interested in
understanding how these cancers evolve and develop resistance to anti-estrogens and anti-HER2
therapies, and then devising ways to combat these patterns of resistance. For instance, we found that
breast cancers that are exposed to antiestrogen therapy develop mutations that cause the estrogen
receptor to remain active, even without any estrogen. So we developed and studied drugs that can
target those mutant estrogen receptors. At the same time, we’re studying the evolutionary process that
allowed the breast tumors to develop those mutations, so that we can develop treatments that will
prevent the mutations from occurring in the first place.

What area of breast cancer research do
you focus on specifically?

Dr. McDAID: Triple negative breast cancer (TNBC) remains one of the most recalcitrant forms of breast cancer, particularly for patients who have inherited mutations in the BRCA1/2 genes. While tubulin inhibitors are still effective for these patients, response rates are lower, and patients can relapse and develop metastatic disease that is resistant to drugs. Even after therapy, some breast cancer cells aren’t killed, but become dormant, and resume growth at a later stage. My lab is developing novel tubulin inhibitors that induce cancer cell death even in TNBCs that no longer respond to drugs like paclitaxel. Another new benefit of these drugs is inducing a very stable form of dormancy that limits the ability of surviving tumor cells to grow back, or to metastasize. We are hopeful that this approach can help women with recalcitrant disease who need additional treatment choices.

DR. CHANDARLAPATY: We focus on two major types of breast cancer: those that have the receptor for the estrogen hormone, and those that have the HER2 receptor. Our lab is interested in understanding how these cancers evolve and develop resistance to anti-estrogens and anti-HER2 therapies, and then devising ways to combat these patterns of resistance. For instance, we found that breast cancers that are exposed to antiestrogen therapy develop mutations that cause the estrogen receptor to remain active, even without any estrogen. So we developed and studied drugs that can target those mutant estrogen receptors. At the same time, we’re studying the evolutionary process that allowed the breast tumors to develop those mutations, so that we can develop treatments that will prevent the mutations from occurring in the first place.

“Over the last forty years, we’ve witnessed the transformative power of breast cancer research.”

“Over the last forty years, we’ve witnessed the transformative power of breast cancer research.”

“Over the last forty years, we’ve witnessed the transformative power of breast cancer research.”

— Dr. Chandarlapaty

— Dr. Chandarlapaty

— Dr. Chandarlapaty

Why is BCRF’s support of breast cancer research so important right now?
Why is BCRF’s support of breast cancer
research so important right now?
DR. McDAID: Breast cancer survivorship is increasing, thanks to the unwavering commitment of organizations like BCRF. But a proportion of survivors with more aggressive or recurrent disease will require future therapy, and the available therapies may not work for them. We still need to develop therapies that can kill cancer cells and spare normal cells. There are several approaches: creating cancer drugs that target tumor cells, devising alternate dosing schedules to limit the cumulative toxicity of the drugs, or developing drugs that are less toxic. BCRF remains steadfast in its support of these important research endeavors.

DR. McDAID: Breast cancer survivorship is increasing, thanks to the unwavering commitment of organizations like BCRF. But a proportion of survivors with more aggressive or recurrent disease will require future therapy, and the available therapies may not work for them. We still need to develop therapies that can kill cancer cells and spare normal cells. There are several approaches: creating cancer drugs that target tumor cells, devising alternate dosing schedules to limit the cumulative toxicity of the drugs, or developing drugs that are less toxic. BCRF remains steadfast in its support of these important research endeavors.
DR. CHANDARLAPATY: Over the last forty years, we’ve witnessed the transformative power of breast cancer research—much of it conducted by BCRF-funded researchers. In the 1980s, it was discovered that the HER2 protein was over-expressed in breast cancers. By the 1990s, a new therapy had been developed to target that protein, and by the early 2000s that therapy was saving lives. The treatments continued to improve over the next two decades, and now we have an explosion of anti-HER2 therapies that can improve outcomes for many patients. However, there are many cancers that don’t have HER2 proteins, or that develop resistance to our best therapies, and we still need to find ways to help these patients. This requires time and innovation, and BCRF really fosters innovation in its research program.

DR. CHANDARLAPATY: Over the last forty years, we’ve witnessed the transformative power of breast cancer research—much of it conducted by BCRF-funded researchers. In the 1980s, it was discovered that the HER2 protein was over-expressed in breast cancers. By the 1990s, a new therapy had been developed to target that protein, and by the early 2000s that therapy was saving lives. The treatments continued to improve over the next two decades, and now we have an explosion of anti-HER2 therapies that can improve outcomes for many patients. However, there are many cancers that don’t have HER2 proteins, or that develop resistance to our best therapies, and we still need to find ways to help these patients. This requires time and innovation, and BCRF really fosters innovation in its research program.
The Breast Cancer Research Foundation is the largest private funder of breast cancer research in the world. More than 44,000 lives are lost to breast cancer in the U.S. each year.
The Breast Cancer Research Foundation is the largest private funder of breast cancer research in the world. More than 44,000 lives are lost to breast cancer in the U.S. each year.
Learn More Learn More

*From now through July 31, 2025, while supplies last, David Yurman will donate 20% of the purchase price from the designs on this page, along with $16 of the $20 purchase price from the pink rubber Cable bracelet to BCRF. Applicable to full-priced sales and available only in DY retail stores and at davidyurman.com (offer not valid in outlets, shop in shops, or any concession locations).

*From now through July 31, 2025, while supplies last, David Yurman will donate 20% of the purchase price from the designs on this page, along with $16 of the $20 purchase price from the pink rubber Cable bracelet to BCRF. Applicable to full-priced sales and available only in DY retail stores and at davidyurman.com (offer not valid in outlets, shop in shops, or any concession locations).